Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Elixirgen Therapeutics, Inc. logo — Reimagine the Power of RNA

Elixirgen Therapeutics, Inc.

Reimagine the Power of RNA

Founded 2017 United States Baltimore, United States 13 employees Venture round Total: $25.91M Biotechnology, Health Care +1

General Information

Company Name Elixirgen Therapeutics, Inc.
Founded Year 2017
Location United States Baltimore, United States
Employees 13
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Elixirgen Therapeutics, Inc.. To contact Elixirgen Therapeutics, Inc., visit elixirgentx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Elixirgen Therapeutics, Inc. compare?

A PDF of Elixirgen Therapeutics, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Elixirgen Therapeutics, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a biotechnology startup that is making significant strides in the field of RNA therapeutics. The company's focus lies in developing innovative therapies, including cell and gene therapies, to address a wide range of diseases such as rare and genetic disorders, as well as aging-related issues. They have three key technologies driving their advancements. Their Bobcat mRNA™ technology has demonstrated promising preclinical results in restoring muscular function in models of Duchenne muscular dystrophy, without any associated safety concerns. Another technology, controllable self-replicating (c-srRNA™), aims to improve efficacy by controlling gene expression and reducing off-target effects. Additionally, their ZSCAN4 technology is being tested in a Phase 1/2 clinical trial to extend telomeres in patients with telomere biology disorders, showing initial signs of potential success. Elixirgen Therapeutics, founded in 2017, recently secured a $7.00M Venture Round investment in November 2023, indicating a continued interest from investors in the company's potential. This Baltimore-based company operates from the Science + Technology Park at Johns Hopkins. Elixirgen Therapeutics is certainly a company to watch as it continues to reimagine the power of RNA in therapeutic innovations.

Business keywords: RNA therapeutics, mRNA technology, cell and gene therapies, rare and genetic diseases, aging-related disorders, Duchenne muscular dystrophy, c-srRNA™ technology, telomere biology disorders, stem cell biology, regenerative medicine, Johns Hopkins Science + Technology Park, biotechnology company, intellectual property, drug development, clinical-stage

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $7.00M -
09 Nov 2023
Debt Financing $5.00M -
28 Sep 2022
Venture Round $4.20M -
17 Feb 2021
Venture Round $5.71M -
02 Dec 2019
Series A $4.00M 1
The University of Tokyo Edge Capital
The University of Tokyo Edge Capital
22 Jun 2018

Elixirgen Therapeutics, Inc. Alternatives & Competitors

View All Alternatives
Elixirgen Therapeutics, Inc. vs
Locanabio, Inc.
Locanabio, Inc. United States

Creating RNA-targeting gene therapies to treat devastating diseases

Series B
7 employees
Biotechnology, Health Care
Elixirgen Therapeutics, Inc. vs
Code Biotherapeutics
Code Biotherapeutics United States

Pioneering targeted delivery of precision genetic medicines

Series A
23 employees
Biotechnology, Health Care
Elixirgen Therapeutics, Inc. vs
Benitec Biopharma Inc.
Benitec Biopharma Inc. United States

Silencing genes for life

Post-IPO Equity
16 employees
Biotechnology, Health Care
View all alternatives

FAQ About Elixirgen Therapeutics, Inc.

Reimagine the Power of RNA
Elixirgen Therapeutics, Inc. was founded in 2017.
Elixirgen Therapeutics, Inc. is headquartered in Baltimore, United States.
Elixirgen Therapeutics, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on RNA therapeutics, mRNA technology, cell and gene therapies and rare and genetic diseases.
Elixirgen Therapeutics, Inc. has approximately 13 employees.
Elixirgen Therapeutics, Inc. has completed 5 funding rounds, raising a total of $25.91M. The latest funding stage is Venture round.
Top alternatives and competitors to Elixirgen Therapeutics, Inc. include Locanabio, Inc., Code Biotherapeutics, Benitec Biopharma Inc., Solid Biosciences, AgeX Therapeutics, Inc. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elixirgen Therapeutics, Inc. and Locanabio, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Elixirgen Therapeutics, Inc., https://bouncewatch.com/company/elixirgen-therapeutics-inc, updated 14 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout